Showing posts with label pandemic preparedness. Show all posts
Showing posts with label pandemic preparedness. Show all posts

Sunday, November 8, 2026

Broad #vaccine #protection against globally diverse #influenza #H5Nx viruses

 


Summary

Influenza A/H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide. The severity of human infections varies substantially between different H5 clades and neuraminidase (NA) reassortants, creating unpredictable pandemic risk. Existing H5 vaccines, typically based on a single hemagglutinin (HA) strain, cannot keep pace with this natural variation. To address this problem, we computationally engineer HA, NA, and M2 antigens representing the global antigenic space of circulating H5Nx viruses, prioritizing N1 and N6 subtypes associated with the highest threat in humans. The resulting digitally immune-optimized mRNA vaccine, DVX-panH5Nx, elicits broad HA neutralization and NA inhibition across divergent clades in mice and ferrets. Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.


Source: Cell Reports Medicine Journal, https://doi.org/10.1016/j.xcrm.2026.103131

____

Immunogenicity and #safety of two priming doses of an MF59-adjuvanted cell-based #H5N8 #influenza #vaccine in healthy persons aged ≥18 years



Abstract

Background

Increased transmission of avian influenza from animals to humans has elevated the risk of an H5 pandemic.

Methods

This phase 2, randomized, observer-blind, multi-center trial assessed the immunogenicity and safety of homologous priming with an MF59-adjuvanted, cell-based H5N8 A/Astrakhan/3212/2020 clade 2.3.4.4b vaccine (aH5N8c). We enrolled adults age ≥18 years, equally stratified into 18–64 (including a poultry-worker subset) and ≥65 year cohorts. Primary and secondary outcomes were homologous antibody responses against H5N8 measured in all participants by hemagglutination inhibition (HI) and in a subset by microneutralization (MN) assays on Days 1, 22, and 43. Solicited adverse events (AEs) were monitored for 7 days post-vaccination, with unsolicited AEs tracked throughout Day 43.

Results

239 participants were vaccinated (18–64 years, n = 121; ≥65 years, n = 118). At Day 43 (21 days post second aH5N8c dose), geometric mean fold increases (GMFI) were 13.7 for the 18–64 cohort and 10.2 for the ≥65 cohort. HI seroconversion rates were 75.8% (95% CI 66.1–83.8%) for the 18–64 cohort and 71.0% (61.1–79.6%) for the ≥65 cohort. HI titers ≥1:40 were achieved in 75.8% (66.1–83.8%) and 73.0% (63.2–81.4%) of participants, respectively. MN seroconversion rates were 80.6% (68.6–89.6%) and 70.0% (56.8–81.2%), while MN titers ≥1:40 were 83.9% (72.3–92.0%) and 86.7% (75.4–94.1%), respectively. No notable differences in immune responses by poultry worker status were observed. Most solicited AEs were mild or moderate, resolving within 3 days. Unsolicited AEs were reported by 16.7% participants by Day 43.

Conclusion

These data support the use of the MF59-adjuvanted, cell-based monovalent H5N8 vaccine as a public health intervention against H5 influenza.


Source: Vaccine Journal, https://doi.org/10.1016/j.vaccine.2026.129279

____

Saturday, October 24, 2026

Can #Hantavirus cruise into the next #pandemic?

 


Abstract

Despite concerns arising from a recent ship-associated outbreak on the M/V Hondius cruise, current evidence suggests that Andes virus (ANDV) poses a low pandemic risk. Nevertheless, viral evolution, ecological changes, and reservoir host dynamics could drive future emergence of ANDV, underscoring the need for improved surveillance, diagnostics, therapeutics, and vaccine preparedness.

Source: 


Link: https://doi.org/10.1590/0074-02760260231

___

Wednesday, October 14, 2026

Mice immunized with #N1 NA in a single cycle infectious virus or in a recombinant nanoparticle #vaccine are protected against lethal challenge with HPAI #H5N1 influenza

 


Abstract

The recent spillover of highly pathogenic (HP) H5N1 clade 2.3.4.4b into dairy cattle and other mammalian species has been concerning. Vaccine candidates that can be rapidly synthesized and implemented are key countermeasures for protecting the human population against emerging pathogens. Here we examine the use of a pH1N1 virus lacking the genetic material for hemagglutinin (HA), limiting the infection to a single cycle (sciIAV) or Cobalt lipid-porphyrin nanoparticles decorated with neuraminidase (NA) of HPAI H5N1 (N1-CoPoP) as vaccine candidates. C57BL/6 mice that were inoculated intranasally with a single dose of pH1N1 sciIAV did not differ in serum NA antibody compared to uninoculated mice. However, mice that were inoculated intramuscularly with the N1-CoPoP alone or in combination with pH1N1 sciIAV had increased N1 IgG antibodies. Upon lethal challenge with HPAIV H5N1, all mice inoculated with either pH1N1 sciIAV or N1-CoPoP were protected from weight loss, unlike unvaccinated mice with substantial body weight losses that succumb to viral infection between 7 and 10 days post infection (dpi). Both pH1N1 sciIAV and N1-CoPoP immunization minimized viral infection such that only one mouse receiving pH1N1 sciIAV had detectable viral titer in the lungs at 4 dpi. By 6 dpi, no mouse inoculated with pH1N1 sciIAV and/or N1-CoPoP had detectable virus in nasal turbinates, lungs or the brain, unlike the high viral titers found in uninoculated mice. Both pH1N1 sciIAV and N1-CoPoP were protective and should be investigated further as alternative vaccine candidates.


Competing Interest Statement

J.F.L. holds interest in POP Biotechnologies. Other authors declare no competing interests.


Funder Information Declared

American Lung Association, https://ror.org/01p3rh655

Texas Biomedical Research Institute

Douglass Foundation

Source: 


Link:  https://doi.org/10.64898/2026.10.11.758125

____

Wednesday, October 7, 2026

Zoonotic #influenza #H5 #vaccination in #humans in #EU/EEA - Assessment - 7 October 2026 (ECDC, summary)

 


{Summary}

Zoonotic influenza A(H5) vaccination in humans in the EU/EEA | Assessment

7 October 2026


    Highly pathogenic avian influenza A(H5N1) continues to circulate widely in wild birds and cause outbreaks in poultry and other animals across Europe. 

    Despite extensive circulation, human infections remain rare and no human cases have been confirmed in the EU/EEA to date. 

    Considering this, ECDC assesses the risk from A(H5N1) viruses circulating in Europe as low for the general population and low to moderate for people occupationally or otherwise exposed to infected animals or contaminated environments.  


Key findings

    ° Twenty-seven of 30 EU/EEA countries responded to the survey on influenza A(H5) vaccination in humans – national plans and implementation status in EU/EEA. 

        § Eight countries reported having national A(H5) vaccination recommendations in place, eight were currently developing them, and 11 had no plans at the time of the survey. 

    ° Implementation of the plans remained limited: five countries had started vaccination campaigns (Austria, Finland, Lithuania, the Netherlands and Portugal) and three planned to do so within one year. 

        § Priority groups most commonly included in the cohort to be vaccinated were veterinarians and animal-health staff, culling teams, laboratory staff and workers in farming and the poultry sector.  

    ° Most countries reported that they are monitoring or planning to monitor vaccine uptake; the majority through immunisation registries. 

    ° Reported vaccine uptake in reporting countries was generally low outside laboratory settings, but data were incomplete and not comparable across countries.  

    ° Overall, results were heterogeneous in the EU/EEA due to variation in national recommendations, implementation plans, delivery arrangements and uptake monitoring.  

        § For preparedness purposes, countries would benefit from clearly defined programme objectives and scenario-based triggers, tested delivery pathways, targeted communication and uptake-monitoring plans. 

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/zoonotic-influenza-ah5-vaccination-humans-eueea

____

Saturday, October 3, 2026

#Antibodies targeting a conserved cryptic epitope at the #influenza hemagglutinin head-stem interface via distinct binding modes

 


Abstract

Influenza A virus continues to pose pandemic threats, as demonstrated by the recent global spread of highly pathogenic H5N1 strains. Consequently, the development and characterization of vaccines targeting zoonotic influenza subtypes have become a major focus of the field. In this study, we characterize two broadly reactive antibodies previously isolated from H5N1 vaccinees. Although they have distinct immunoglobulin germline gene usage and binding modes, cryo-EM analysis shows that both antibodies share a highly conserved cryptic epitope at the interface of the hemagglutinin (HA) head and stem domains. The antigenicity of this epitope is influenced by natural amino acid variation at residue 293 of HA subunit 1, and its access is facilitated by acid-induced conformational change of HA. Nevertheless, both antibodies are non-neutralizing and possess only marginal protective efficacy against seasonal and H5N1 viruses in vivo, thus representing suboptimal vaccine responses. Overall, our findings expand the interactions of cross-reactive antibodies with an under-characterized HA epitope and provide insights for next-generation influenza vaccine design.


Competing Interest Statement

N.C.W. consults for HeliXon. All authors declare no other competing interests.


Funder Information Declared

Research Grants Council of the Hong Kong Special Administrative Region, China, HKU C7053-24G

Health and Medical Research Fund, no. 24230352

NIH/NIGMS, GM158411

Vallee Scholars Program


Source: 


____

Cross-clade #protection against #human #H5N1 isolates by a clade 2.3.4.4b HA #mRNA #vaccine in mice

 


Abstract

The recent spread of clade 2.3.4.4b H5N1 high pathogenicity avian influenza (HPAI) viruses into mammals, despite limited human infections to date, has raised serious public health concerns and highlights the need for rapidly deployable vaccines, such as mRNA-based platforms, to strengthen pandemic preparedness. Here, we evaluated the effectiveness of an mRNA vaccine encoding the HA of NIID-002, a WHO-recommended H5 candidate vaccine virus (CVV) derived from A/Ezo red fox/Hokkaido/1/2022 (clade 2.3.4.4b) against A/Texas/37/2024 (TX37; clade 2.3.4.4b) and A/Cambodia/2311257/2023 (Cam23; clade 2.3.2.1e). The mRNA was formulated with ssPalmO, a low-inflammatory self-degradable ionizable lipid nanoparticle (LNP). BALB/c mice were immunized intramuscularly twice with the mRNA-LNP vaccine containing either 1 μg or 10 μg of H5 HA mRNA. After boosting, strong, dose-dependent serum IgG responses against NIID-002 HA were detected by ELISA. The mice were then challenged with a lethal dose of homologous TX37 or heterologous Cam23. All mice in the 10-μg group survived both challenges, demonstrating robust cross-clade protection. In the 1-μg group, complete protection without significant body weight loss was observed against TX37, whereas partial protection was observed following Cam23 challenge. Viral titers were significantly reduced in multiple tissues of the vaccinated mice compared to the unvaccinated controls. Our findings demonstrate that the NIID-002-HA mRNA vaccine confers protection against homologous and heterologous zoonotic H5N1 strains in a mouse model. This low-inflammatory ssPalmO-LNP platform thus supports safe, rapid vaccine development against emerging H5N1 viruses with pandemic potential.

Source: 


Link: https://doi.org/10.1016/j.vaccine.2026.129215

____

Friday, October 2, 2026

Multi-Country #Human-to-Human #Andes Virus #Outbreak on a Cruise #Ship: A Disaster #Report on Prehospital, Health Care Facility, and Public Health System Challenges – Essential Knowledge for Frontline Clinicians

 


Abstract

The Andes Virus (ANDV) outbreak reported on May 2, 2026, aboard a luxury vessel departing from Ushuaia, Patagonia, Argentina, was caused by an Orthohantavirus unique in its person-to-person transmissibility in contrast to zoonotic transmission characteristic of better-known hantaviruses. Containment required coordinated international management because passengers and crew embarked and disembarked at several international ports-of-call prior to outbreak recognition, resulting in cross-border transmission potential. Among those who disembarked, several traveled on flights to various destinations. Cases subsequently manifested in multiple countries, including Tristan da Cunha, Spain, France, Switzerland, South Africa, Canada, and The Netherlands. Upon notification, international health authorities implemented containment measures, such as contact tracing, quarantine, and isolation. Uniquely, ANDV poses distinctive risks due to its immediately prodromal presymptomatic transmission potential, initial non-specific flu-like symptoms, prolonged incubation period, conceivable long-term neurologic and endocrinologic sequalae, high case fatality rates (CFRs), and possibility of international dissemination. This report describes the successful management of a multi-national outbreak associated with cruise-ship travel, a setting with unique challenges. It also examines implications and challenges for prehospital, health care facility, and public health systems for future ANDV outbreaks. The event was characterized by delayed recognition, international spread, and complex coordination across multiple jurisdictions and sectors, including medical and public health authorities, policy- and decision-makers, crisis and emergency risk-communication experts, media, logistics, transportation, and security. Rapid implementation of public health measures coupled with clinician implementation of the Identify-Isolate-Inform (3I) model, a clinical framework to detect and prevent the spread of infectious disease, at the prehospital and health care facility levels are critical actions that can contain future ANDV outbreaks.

Source: 


Link: https://doi.org/10.1017/S1049023X26109108

____

Wednesday, September 23, 2026

Comparison of #Baloxavir-Based Combinations and Monotherapies for Treating #Influenza #H5N1 Clade 2.3.4.4b Virus #Infection in Mice

 


Abstract

Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus continues to cause animal outbreaks and sporadic zoonotic infections. In a mouse model of lethal influenza disease, we compared oseltamivir, baloxavir, and molnupiravir monotherapies with 2-drug combinations. Baloxavir-based combinations improved survival, reduced lung viral loads, and prevented extrapulmonary dissemination, supporting H5N1 preparedness strategies.

Source: 


Link: https://doi.org/10.3201/eid3210.260186

____

Monday, September 21, 2026

#Global #framework to accelerate #action on avian #influenza (WOAH/FAO/WHO, September 21 '26, summary)

 


Required citation: FAO, WHO, WOAH and CMS. 2026. Global framework to  accelerate action on avian influenza. Rome. https://doi.org/10.4060/ce1712en

The designations employed and the presentation of material in this information product do not imply the expression

of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO), the World

Health Organization (WHO), the World Organisation for Animal Health (WOAH) or the Convention on the Conservation of

Migratory Species of Wild Animals (CMS), concerning the legal or development status of any country, territory, city or area

or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or

products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or

recommended by FAO, WHO, WOAH or CMS in preference to others of a similar nature that are not mentioned.

The responsibility for the interpretation and use of the material lies with the reader, and in no event shall FAO, WHO,

WOAH or CMS be liable for damages arising from such interpretation or use.

ISBN 978-92-5-141028-8 [FAO]

ISBN (WHO) 978-92-4-012544-5 (electronic version)

ISBN (WHO) 978-92-4-012545-2 (print version)

© FAO, WHO and WOAH, 2026

Some rights reserved. This work is made available under the Creative Commons Attribution-NonCommercial-ShareAlike

3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/ )

(...)

1. Introduction

Avian influenza is a complex global challenge with consequences for animal health,

human health, biodiversity, food security and livelihoods. In recent decades, high

pathogenicity avian influenza (HPAI) viruses have spread across continents, become

established in wild bird populations, affected an increasing range of mammalian species

and caused unprecedented impacts on wildlife, poultry production and associated

economies. These impacts are occurring alongside other environmental pressures

including climate change, habitat degradation and biodiversity loss.

Recognizing these challenges, the Food and Agriculture Organization of the United

Nations (FAO), the World Health Organization (WHO), the World Organisation for Animal

Health (WOAH) and the Convention on the Conservation of Migratory Species of Wild

Animals (CMS) have developed this global framework to strengthen collaboration on

avian influenza through a One Health approach.

This high-level framework is not intended to replace existing mandates, strategies or

technical guidance. Rather, it adds value by showing how existing mandates, strategies

and technical mechanisms can be better connected, aligned and communicated as part

of a shared One Health response to avian influenza. It reflects a recognition that no single

sector nor institution can address avian influenza alone, and that sustainable solutions

require coordinated efforts that integrate human, animal and environmental dimensions.

Developed through a participatory and consultative process, the framework draws

on the comparative strengths and roles of each organization (Figure 1). It emphasizes

the importance of human, domestic animal and wildlife surveillance, including in wild

birds, poultry and susceptible mammalian species, timely information and data sharing,

strong laboratory and workforce capacities, effective risk communication and sustained

investment in prevention and preparedness. It reinforces the principle that protecting

health is inseparable from protecting ecosystems and ensuring resilient agrifood systems.

Given the accelerating risks and impacts of avian influenza, there is an urgent need to

translate this framework into concrete action. This will require enhanced global support,

including increased and sustained investment in prevention, preparedness, surveillance,

mitigation and response capacities across sectors. The four organizations call on

governments, donors and partners to prioritize avian influenza within broader health

security and development agendas, and to mobilize the resources necessary to support

coordinated, country-led implementation of a One Health approach.

(...)

Source: 


Link: https://doi.org/10.4060/ce1712en

____

Saturday, September 12, 2026

Respiratory #pandemic #risk in the #Anthropocene: A #OneHealth #framework and #GISRS+ agenda

 


Highlights

    • Respiratory pandemics are now a structural feature of the Anthropocene.

    • H5Nx and SARS-related CoVs are identified as leading pandemic candidates.

    • A geographic mismatch exists between spillover risk and surveillance.

    • A multidimensional GISRS+ agenda is proposed for proactive One Health.


Abstract

Recent epidemics and pandemics caused by respiratory viruses, alongside the animal panzootic spread of highly pathogenic avian influenza A(H5Nx), have become a structural feature of the Anthropocene, yet responses remain largely reactive. This review integrates findings from WHO's Global Influenza Surveillance and Response System (GISRS) and related surveillance data (2000–2024), epidemiological studies of influenza A virus, SARS-CoV, MERS-CoV, SARS-CoV-2, and H5Nx, and One Health literature. We examine major groups of respiratory viruses and identify mismatches between risk and surveillance by focusing on spillover potential from animal hosts, human-to-human transmission and its controllability, and Anthropocene characteristics that increase epidemic risk. The analysis indicated that SARS-related coronaviruses and influenza A viruses, particularly H5Nx, are among the leading candidates based on currently available evidence because they have large reservoirs in animal hosts and spillover to humans is highly probable. The previous presymptomatic spread of SARS-CoV-2 and recent mammalian adaptation in H5N1 clade 2.3.4.4b highlight limitations of the traditional symptom-based and pathogen-specific surveillance system. Spillover events tend to occur in tropical and subtropical regions in low- and middle-income countries, but most genomic surveillance is in high-income countries. We propose interventions that address the upstream, midstream, downstream processes of epidemics. Upstream interventions are primary prevention measures related to land use, livestock, wildlife, and urban environments; midstream interventions are GISRS+-based pathogen-agnostic genomic and metagenomic early warning systems triggered by One Health; and downstream interventions include vaccines, antivirals, non-pharmaceutical interventions, and engineering with equity-centred global governance and sustainable financing.

Source: 


Link: https://doi.org/10.1016/j.onehlt.2026.101553

____

Divergent #antibody-mediated population #immunity to #H5, #H7 and #H9 subtype potential #pandemic #influenza viruses

 


Abstract

Influenza continues to cause significant mortality globally and possesses substantial pandemic potential. Assessing pandemic risk requires a clear understanding of existing population immunity. Leveraging a unique large-scale cohort of human sera, we evaluated total and neutralising antibody-mediated immunity to multiple haemagglutinin (HA) proteins, including those from subtypes with high pandemic potential. Our analysis reveals that population immunity is heterogeneous, with distinct age-dependent differences in responses to H5, H7, and H9 avian influenza subtypes. These shifts align with historical circulation patterns of seasonal H1N1 and H3N2 human viruses. Notably, H7 viruses are primarily neutralised through head domain epitopes, while H5 viruses are targeted mainly via stem epitopes, although in both instances some neutralisation occurred via receptor binding site-adjacent epitopes. Furthermore, H7 responses were dominated by non-glycan-targeted IgG2 antibodies, whereas H5 responses were primarily IgG1-mediated. These findings highlight varying levels of susceptibility to influenza across the population, supporting vaccination approaches informed by exposure history.


Competing Interest Statement

CPT has received lecture fees from Moderna.

Source: 


Link: https://www.medrxiv.org/content/10.1101/2025.09.08.25335309v2

____

Saturday, September 5, 2026

#Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted #influenza #H5N8 #vaccine

 


Abstract

Highly pathogenic avian influenza (HPAI) A(H5) viruses can be transmitted from infected birds to various mammalian species, including humans. Avian influenza viruses (AIVs), members of the Orthomyxoviridae family, possess segmented RNA genomes prone to reassortment, favoring the emergence of novel genetic traits that may alter transmissibility, pathogenicity, and antigenicity. Although no sustained human-to-human transmission has been reported, the potential adaptation of these viruses poses a significant pandemic threat. This study aimed to evaluate the non-clinical safety, toxicity, and humoral immune responses induced by an adjuvanted H5 influenza vaccine in rats and rabbits, to support future clinical safety trials in humans. Male and female Wistar rats and New Zealand rabbits were observed for 14, 28, and 90 days after receiving two intramuscular doses of the H5N8 vaccine (15 μg HA/dose) formulated with the IB160 oil-in-water emulsion adjuvant. No systemic comorbidities, central nervous system alterations, or relevant clinical signs were observed. Hematological parameters remained within normal ranges, with total and differential leukocyte counts showing only minor fluctuations (<1% of total leukocytes). Mild biochemical variations in urea and hepatic transaminase levels were not correlated with histopathological alterations. The vaccine elicited a robust humoral response soon after immunization, with all groups reaching protective HAI-antibody titers. Although antibody levels declined over time, particularly in males, they remained significantly above baseline, indicating durable immunological memory. Furthermore, the vaccine induced a specific cellular immune response, confirmed by IL-2 and TNF production by antigen-specific T lymphocytes in splenic cell cultures after the booster dose. In conclusion, the H5N8 vaccine with the IB160 adjuvant was well tolerated locally and systemically, without compromising vital organ function. The safety and immunogenicity findings are consistent with expectations for adjuvanted influenza vaccines, demonstrating strong and durable humoral and cellular immune responses.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008583?via%3Dihub

____

Friday, September 4, 2026

Lessons Learned During 2024‒25 Highly Pathogenic Avian #Influenza #H5N1 Virus #Outbreak Response in #USA: Experience of State and Local Public Health Departments

 


Abstract

Objectives. 

To describe challenges and lessons learned during state and local health department responses to the 2024‒2025 highly pathogenic avian influenza A(H5N1) outbreaks.

Methods. 

We conducted semistructured interviews from August to November 2025 with Department of Health and Agriculture staff from states with confirmed or probable A(H5N1) human cases. We conducted 15 total interviews with 37 participants from 10 US states. Interview transcripts were inductively and deductively coded to identify generalizable lessons that might improve future outbreak response efforts.

Results. 

Key themes included difficulty accessing farms and reaching at-risk populations; lack of sufficient guidelines for proactively responding to zoonotic outbreaks that could have human health implications; the importance of maintaining preparedness planning, capacity, and infrastructure; and uncertainty around future capacity to respond to outbreaks because of resource constraints and changes in federal leadership.

Conclusions. 

Although this study focused on responses to A(H5N1) outbreaks, the findings are indicative of the nation’s overall readiness for biological threats. Prioritization of capacity building for infectious disease outbreaks, including robust health department funding to support continued disease surveillance, is critical to prevent more widespread transmission. 

(Am J Public Health. Published online ahead of print September 3, 2026:e1–e7. https://doi.org/10.2105/AJPH.2026.308656)

Source: 


Link: https://ajph.aphapublications.org/doi/10.2105/AJPH.2026.308656

____

Friday, August 28, 2026

Modeling the #impact of respiratory disease #outbreaks on the #US #agricultural #workforce

 


Abstract

Background: 

Emerging respiratory disease outbreaks pose a major threat to food production systems. Agricultural workers face health disparities that amplify their susceptibility to respiratory pathogens, yet the consequences for worker health and food production remain poorly understood. 

Methods: 

We developed a household-structured susceptible-infectious-recovered (SIR) transmission model to compare disease dynamics between agricultural workers and the general U.S. population across six regions. We simulated outbreaks across a range of epidemiological scenarios and assessed productivity losses in California for three labor-intensive crops (oranges, iceberg lettuce, strawberries) with different harvest seasonalities. 

Results: 

We show that, for a baseline reproduction number of R0 = 2.0, the peak disease prevalence among agricultural workers is 1.41-1.69 times higher than that of the general population across regions, and final outbreak sizes are 1.29-1.42 times higher. Household structure accounts for 54%-68% of the disease disparity. Peak productivity losses range from 0.50%-0.63% across crops, translating to millions in lost potential revenue. At higher transmissibility and severity (R0 = 3 and assuming all infections are symptomatic), losses are 2.4 times higher. 

Conclusions: 

Household crowding may lead to disproportionate respiratory disease burden among agricultural workers that is exacerbated by vaccination and obesity disparities, highlighting the need for targeted outbreak preparedness and mitigation strategies in the agricultural sector to maintain food system resilience and support public health in these communities.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.03.31.26349871v2

____

Tuesday, August 18, 2026

A novel candidate #vaccine virus derived from #Japan's first #mammalian case of clade 2.3.4.4b #H5N1 highly pathogenic avian #influenza virus

 


Abstract

The development of candidate vaccine viruses (CVVs) for pre-pandemic preparedness requires attenuation of pathogenicity while maintaining immunogenicity. In this study, we developed and characterized NIID-002, a reassortant virus derived from A/Ezo red fox/Hokkaido/1/2022 (H5N1; clade 2.3.4.4b), to evaluate its suitability as a candidate vaccine. NIID-002 exhibited markedly reduced pathogenicity compared with its parental strain, while retaining broad antigenic reactivity and protein yield comparable to other clade 2.3.4.4b CVVs. In mammalian models, NIID-002 demonstrated strong attenuation, causing no lethal infection in mice and only minimal weight loss with limited viral replication in ferrets. Antisera raised against NIID-002 reacted broadly with recent wild-type H5N1 isolates, suggesting potential broad protection. Protein yield analysis confirmed a production efficiency comparable to that of other CVVs within the same clade, supporting its feasibility for large-scale vaccine manufacturing. Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency. These findings highlight its potential as a candidate H5N1 vaccine and underscore the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008571?via%3Dihub

____

#Community #engagement strategies for preventing recurrent #Nipah virus #outbreaks in #Bangladesh and #India: adapting a framework for outbreak preparedness and response

 


Abstract

The Nipah virus (NiV) infection is a highly fatal zoonotic disease with pandemic potential which has led to recurrent outbreaks in Bangladesh and India. While transmission pathways, including contaminated date palm sap and human-to-human spread, are increasingly identified, significant uncertainties remain. With no approved therapeutics or vaccines, prevention depends on addressing ecological and behavioural drivers of transmission. This viewpoint draws on selected evidence from NiV outbreaks and response to other zoonotic disease epidemics, such as Ebola, rabies, and the Marburg virus disease, we seek to foster discussion on why community engagement could be central to NiV prevention and preparedness. We highlight the relevance of community engagement through a spectrum of its intensity, which distinguishes between community-oriented, community-based, community-managed, and community-owned approaches. Adapting an existing model, we discuss how community engagement principles can be applied to tackle recurring NiV outbreaks in Bangladesh and India. By aligning interventions with sociocultural realities, community engagement can improve acceptability, enhance early detection, strengthen outbreak response, and support preparedness for future vaccine and therapeutic research. However, evidence specific to NiV remains limited and lessons from other diseases should be applied judiciously. In the absence of medical countermeasures, participatory, locally grounded approaches offer a sustainable pathway to reduce recurrent outbreaks and prevent future spillover events.

Source: 


Link: https://jogh.org/2026/jogh-16-03024

____

Enhanced #Pathogenicity and Contact #Transmissibility of #Human-origin Avian #Influenza #H5N1 Clade 2.3.4.4b Genotype B3.13 Compared to D1.1 in #Ferrets

 


Abstract

Since its emergence in 2020, multiple genotypes of the H5N1 clade 2.3.4.4b have been identified, with B3.13 and D1.1 emerging in the USA as two major and concerning genotypes. However, their relative pathogenicity and transmissibility in mammals have not been fully elucidated. We compared the pathogenicity and transmissibility of the first two human H5N1 clade 2.3.4.4b cases caused by B3.13 in Texas (A/Texas/37/2024; HPhTX B3.13) and D1.1 in Louisiana (A/Louisiana/12/2024; HPhLA D1.1) in a ferret model of infection and transmission. HPhTX B3.13 infection resulted in more severe clinical disease and enhanced viral shedding, with evidence of increased transmission relative to HPhLA D1.1. Histopathological analysis revealed more extensive lung pathology in animals infected with HPhTX B3.13, consistent with increased viral loads and inflammatory responses. Importantly, both genotypes showed no significant differences in reactivity to ferret sera raised against candidate vaccine virus (CVV) strains, receptor binding properties, or neuraminidase (NA) activity and thermostability. Whole-genome sequencing revealed no adaptive mutations in HPhTX B3.13 following infection or transmission. In contrast, HPhLA D1.1 showed rapid acquisition of the mammalian-adaptive mutation E627K in infected ferrets and both E627K and Q194K in the only fatal contact animal. Both mutations were associated with enhanced polymerase activity and computational analyses suggested that they enhance interactions with the mammalian host factors ANP32A and B. Our findings indicate that B3.13 is already well adapted for mammalian infection and transmission whereas D1.1 retains evolutionary potential through the rapid acquisition of adaptive mutations, highlighting important genotype-specific differences relevant to zoonotic risk assessment and pandemic preparedness.


Competing Interest Statement

The A.G.-S. laboratory has received research support from Avimex, Dynavax, Pharmamar, and Accurius, outside of the reported work within the last three years. A.G.-S. has consulting agreements for the following companies involving cash and/or stock within the last three years: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, Avimex, Pagoda, Accurius, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Virofend, Prosetta and A.A.C.T., outside of the reported work. A.G.-S. has been an invited speaker in meeting events within the last three years organized by Seqirus, Novavax and Hipra. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside of the reported work. The Icahn School of Medicine at Mount Sinai has licensed some of these inventions to Medimmune, Avimex, Leinco Technologies, Castlevax, Virofend, Kerafast, Cell Signaling, EMD Millipore, Genentech, Paratus and Nura Bio, and as a result receives financial compensation. Subject to Mount Sinai receiving such financial consideration, AG-S will receive a portion of that consideration pursuant to the terms of the Mount Sinai Intellectual Property Policy. All other authors declare no commercial or financial conflict of interest.


Funder Information Declared

NIH/NIAID, 75N93021C00014

Horizon Europe Program, KAPPA-FLU no. 101084171

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.08.10.744032v1

____

Wednesday, August 12, 2026

Protective effect of #H5N8 stockpiled #vaccine against a virus genetically identical to a #human isolate of #bovine #H5N1 #influenza virus

 


Summary

Background

Since early 2024, highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b have caused extensive outbreaks in dairy cattle in the United States, with spillover into mammalian species, including humans. A bovine-derived A(H5N1) virus isolated from a human case retains high pathogenicity and transmissibility in mammalian models, highlighting its pandemic potential. Stockpiled pre-pandemic influenza vaccines are intended to provide early protection before strain-matched vaccines are available; however, their protective efficacy against bovine A(H5N1) viruses has not been directly evaluated in vivo.

Methods

In this study, we assessed the protective efficacy of an AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8) clade 2.3.4.4b-based influenza vaccine stockpiled in Japan using mouse and ferret models. Vaccinated and unvaccinated animals were challenged with a virus genetically identical to a human isolate of bovine A(H5N1) virus. Neutralising antibody responses, viral replication in organs, and survival were evaluated.

Findings

Vaccination with the AS03-adjuvanted A(H5N8)-based stockpiled vaccine induced robust neutralising antibody responses in both animal models, significantly suppressed viral replication, and conferred complete protection against lethal challenge. In contrast, all unvaccinated mice and ferrets succumbed to infection. These findings demonstrate that the AS03-adjuvanted A(H5N8)-based stockpiled vaccine provides strong cross-protective efficacy against bovine A(H5N1) viruses.

Interpretation

An AS03-adjuvanted A(H5N8)-based vaccine stockpiled in Japan could serve as an immediate countermeasure against bovine A(H5N1) viruses during the early phase of a pandemic.

Funding

This work was supported by grants from the Japan Program for Infectious Diseases Research and Infrastructure (JP20wm0125002) and the Japan Initiative for World-leading Vaccine Research and Development Centers (JP223fa627001) from the Japan Agency for Medical Research and Development.

Source: 


Link: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00314-2/fulltext

____

Thursday, August 6, 2026

Heterologous prime-boost #vaccination against #H5 avian #influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived #H5N6 vaccine

 


ABSTRACT

With increasing H5 avian influenza cases reported globally and the potential for pandemic emergence, induction of cross-reactive antibody responses may represent an important attribute of an effective vaccine. This phase 2 extension study evaluated immunogenicity and safety of MF59-adjuvanted, cell culture-derived H5N6 vaccine (aH5N6c) in adults primed with MF59-adjuvanted, cell culture-derived H5N1 vaccine (aH5N1c) and in unprimed adults. Adults previously primed with two doses of aH5N1c in the parent study V89_18 were randomized to receive two aH5N6c doses (Group 1) or one aH5N6c and one placebo (Group 2) 3 weeks apart. Unprimed adults received two aH5N6c doses (Group 3). Immunogenicity was assessed by hemagglutination inhibition (HI) and microneutralization (MN) assays against the priming (H5N1) and booster (H5N6) strains on Days 1, 8, 22, 43, and 202. Among 258 exposed participants, primed subjects (Groups 1 and 2) showed higher HI geometric mean titers against both strains than unprimed (Group 3) subjects, with MN responses similarly enhanced. Heterologous H5N1 responses were robust in primed subjects (Day 43 HI GMTs: 333–343; seroconversion rates >89%) but minimal in unprimed subjects, with responses persisting to Day 202. Solicited adverse events were mild or moderate, comparable between groups, and consistent with other MF59-adjuvanted pandemic vaccines; no vaccine-related serious adverse events occurred. Heterologous H5N6 booster vaccination in H5N1-primed adults elicited strong cross-reactive immunity against the priming strain, demonstrating long-lasting immune memory for at least 6 y and supporting heterologous prime-boost strategies for pandemic preparedness against emerging H5 outbreaks.

Source: 


Link: https://www.tandfonline.com/doi/full/10.1080/21645515.2026.2712791

____

My New Space

Most Popular Posts